Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-02-14

Clinical Trial Update: Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update on atogepant for prevention of chronic migraine, reporting efficacy, safety, and tolerability results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Atogepant (Atogepant)

Snippet

Sponsor: Allergan | Conditions: Chronic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2023-02-14